Imunon Q1 Net Loss $4.3M; IMNN-001 Phase 2 OS up 14.7 months
Imunon, Inc. reported its first quarter 2026 financial results and provided a business update, highlighting significant progress in its lead candidate, IMNN-001. The final Phase 2 OVATION 2 study data demonstrated a median 14.7-month increase in overall survival for women with newly diagnosed advanced ovarian cancer, with an even greater increase when combined with PARP inhibitors. The company's Phase 3 OVATION 3 trial enrollment is ahead of schedule, and the FDA has aligned with the protocol, confirming a path to BLA filing. Financially, Imunon reported a net loss of $4.3 million for the quarter, an increase from the prior year, primarily due to trial-related expenses for the OVATION 3 study, and held $4.8 million in cash and cash equivalents.
Key Highlights
- IMNN-001 Phase 2 OVATION 2 study showed a median 14.7-month increase in overall survival (45.1 vs. 30.4 months) in ovarian cancer.
- IMNN-001 with PARP inhibitors achieved a median 24.2-month increase in overall survival (65.6 vs. 41.4 months).
- Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is ahead of plan, expected to be completed by Q1 2029.
- FDA has reviewed and is aligned with the Phase 3 protocol, confirming a path to BLA Filing.
- Net loss for Q1 2026 was $4.3 million, or $0.84 per share, compared to $4.1 million, or $3.15 per share, in Q1 2025.
- Operating expenses for Q1 2026 were $4.3 million, up from $4.1 million in Q1 2025.
- Cash and cash equivalents were $4.8 million as of March 31, 2026.
- Company underwent a strategic reorganization in February 2026 to reduce operating expenses and focus on the Phase 3 trial.